Evidence map›Paper›PMID 39399689›Full record

ArticleResearch square2024

PharmRL: Pharmacophore elucidation with Deep Geometric Reinforcement Learning.

Rishal Aggarwal, David R Koes

Abstract readPreprint
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Rishal AggarwalJoint PhD Program in Computational Biology, Carnegie Mellon University-University of Pittsburgh, Pittsburgh, Pennsylvania.
David R KoesComputational & Systems Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.

Funding

New Methods and Tools for Computational Drug Discovery: Diversity SupplementR35GM140753 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KOES, DAVID RYAN · 2021 to 2025
$2.2M
NIGMS NIH HHS R35 GM140753
6 · The paper itself

Abstract

Molecular interactions between proteins and their ligands are important for drug design. A pharmacophore consists of favorable molecular interactions in a protein binding site and can be utilized for virtual screening. Pharmacophores are easiest to identify from co-crystal structures of a bound protein-ligand complex. In this work, however, we develop a deep learning method that can identify pharmacophores in the absence of a ligand. Specifically, we train a CNN model to identify potential favorable interactions in the the binding site, and develop a deep geometric Q-learning algorithm that attempts to select an optimal subset of these interaction points to form a pharmacophore. With this algorithm, we show better prospective virtual screening performance, in terms of F1 scores, on the DUD-E dataset than random selection of ligand identified features from co-crystal structures. We also conduct experiments on the LIT-PCBA dataset and show that it provides efficient solutions for identifying active molecules. Finally, we test our method by screening the COVID moonshot dataset and show that it would be effective in identifying prospective lead molecules even in the absence of fragment screening experiments. Alongside, we provide a Google Colab notebook for ease of use of the developed method.

Indexed as

Machine LearningPharmacophoresProtein-Ligand interactionsVirtual Screening

Identifiers

PMID39399689
PMCPMC11469520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.